Oncimmune Holdings PLC Block Listing Return
13 Marzo 2024 - 6:32PM
RNS Regulatory News
RNS Number : 7651G
Oncimmune Holdings PLC
13 March 2024
13
MARCH 2024
Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Block Listing Return
|
Name of applicant:
|
Oncimmune Holdings plc
|
|
Name of scheme:
|
Oncimmune Holdings Plc 2016
Unapproved and EMI Share Option Plans
|
|
Period of return:
|
15 March 2022 to 12 March
2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
5,787,346
|
|
Plus: The amount by which the block
scheme(s) has been increased since the date of the last return (if
any increase has been applied for):
|
0
|
|
Less: Number of securities
issued/allotted under scheme(s) during period:
|
108,882
|
|
Equals: Balance under
scheme(s) not yet issued/allotted at end of
period:
|
5,678,464
|
For further
information:
Oncimmune
Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated
Adviser and Broker)
Philip Davies, Harry Gooden, James
Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan
Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the UK,
with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLREAXDDFAPLEFA
Grafico Azioni Oncimmune (LSE:ONC)
Storico
Da Mar 2025 a Apr 2025
Grafico Azioni Oncimmune (LSE:ONC)
Storico
Da Apr 2024 a Apr 2025
